DRUG
ALT-801
Injected subcutaneously (SC)
Status
Completed
Phase
Phase 1
Enrollment
100
Locations
1
Results
Not posted
Publications
0
Study summary
This study was a FIH, Phase 1, randomized, double-blind, placebo-controlled, 2-part single-ascending dose (SAD) and multiple-ascending dose (MAD) study of ALT-801 (pemvidutide) in healthy overweight and obese subjects. The purpose of the study was to assess the safety and tolerability in healthy overweight and obese volunteers administered single or multiple repeated doses of ALT-801 (pemvidutide).
This study had 2 parts. Part 1 involved single dose cohorts of ALT-801 (pemvidutide) or placebo taken as a subcutaneous (SC) injection and was approximately 36 days in duration. Part 2 involved multiple dose cohorts of ALT-801 (pemvidutide) or placebo taken once a week for 12 weeks as a SC injection and was approximately 116 days in duration. Each participant enrolled in only one part.
Interventions
DRUG
Injected subcutaneously (SC)
OTHER
Injected subcutaneously (SC)
Timeline
First posted
Sep 23, 2020
Study start
Nov 10, 2020
Primary completion
Oct 29, 2021
Study completion
Oct 29, 2021
Results posted
Not reported
Registry updated
Jun 24, 2025
Outcomes
The Number of Participants with One or More Treatment-Emergent Adverse Events (TEAEs)
Time frame · Part 1 SAD Cohorts: up to Day 26; Part 2 MAD Cohorts: up to Day 42
Pharmacokinetic (PK): Maximum observed concentration (Cmax) of ALT-801
Time frame · Baseline, Day 26
Pharmacokinetic (PK): Area Under the Concentration (AUC) vs Time Curve of ALT-801
Time frame · Baseline to Day 26
Change in body weight
Time frame · Baseline to Week 6
Pharmacodynamic (PD): Change from baseline in magnetic resonance derived proton density fat fraction (MRI-PDFF)
Time frame · Baseline to Week 6
Not reported in the indexed record.
Eligibility
Inclusion Criteria: * Male or female healthy volunteers, age 18 to 60 years, inclusive * Overweight to obese (BMI 25.0 - 40.0 kg/m2) * MRI-PDFF≥ 10% (Part 2 only) * Non-smokers or ex-smokers (must have ceased smoking \> 1 months prior to screening visit) * Subjects must otherwise be in good general health, with no significant medical history, have no clinically significant abnormalities on physical examination at screening, and/or before administration of the initial dose of study medication * Ability and willingness to attend the necessary visits to the study center * Written informed consent signed prior to entry into the study Exclusion Criteria: * Women who are pregnant or breastfeeding * History of pancreatitis * History of or acute significant GI disorder * History of diabetes or use of medications for the treatment of diabetes, or hyperglycemia or HbA1c ≥ 6.5% * History of clinically significant endocrine (eg, hypothyroidism), neurological, GI, cardiovascular (except controlled hypertension and hypercholesterolemia), hematological, hepatic, immunological, renal, respiratory, or genitourinary abnormalities or diseases * History of neoplastic disease, or personal or family history of multiple endocrine neoplasia or medullary cancer of the thyroid, with the following exceptions: 1. Adequately treated non-melanomatous skin carcinoma 2. Female with a history of benign cervical neoplasia if the subject has been compliant with surveillance and treatment as recommended by her physician * Blood pressure \> 150/90 mmHg or heart rate \> 100 beats per minute at screening and at Day -1 * Clinically significant laboratory abnormalities including: Impaired renal function (estimated glomerular filtration rate \[eGFR\] \<60 mL/min/1.73m2) as estimated using the MDRD equation at screening: 1. GFR (mL/min/1.73 m²) = 175 × (SCr/88.4)-1.154 × (Age)-0.203 × (0.742 if female) × (1.212 if African American) (SI units), where SCr is standardized serum creatinine in SI units (µmol/L) and age is in years 2. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) laboratory values \> 2 × upper normal limits 3. Calcitonin \> 50 ng/L - Excessive alcohol consumption defined as \>21 alcohol units per week for males and as \>14 alcohol units per week for females (where 1 unit = half pint of beer, 25 mL of 40% spirit, or 125 mL of wine)
Study locations
Australia. Showing up to 24 locations stored in the fast local snapshot.
Nucleus Networks
Herston, Queensland, Australia
Publications
No PMID-linked publications were present in this registry snapshot.
Related trials
Altimmune, Inc. · Alcohol Use Disorder (AUD)
Phase 2
Completed
100
2026-07
Altimmune, Inc. · Non-Alcoholic Steatohepatitis (NASH)
Phase 2
Completed
212
2026-05
Altimmune, Inc. · Alcohol Liver Disease
Phase 2
Recruiting
100
2026-03
Altimmune, Inc. · NASH - Nonalcoholic Steatohepatitis
Phase 1
Completed
40
2025-06
Altimmune, Inc. · Type 2 Diabetes
Phase 1
Completed
55
2025-06
Altor BioScience · Non-muscle Invasive Bladder Cancer
Phase 1 / Phase 2
Terminated
12
2024-07
Altor BioScience · Transitional Cell Carcinoma of Bladder · Urethra Cancer
Phase 1 / Phase 2
Completed
68
2024-06
Altor BioScience · Relapsed or Refractory Multiple Myeloma
Phase 1 / Phase 2
Terminated
6
2024-06
Related PeptideStat pages
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.